Cargando…
Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
BACKGROUND: New-generation cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470615/ https://www.ncbi.nlm.nih.gov/pubmed/32883348 http://dx.doi.org/10.1186/s12974-020-01824-2 |
_version_ | 1783578617626755072 |
---|---|
author | Jarius, Sven Pellkofer, Hannah Siebert, Nadja Korporal-Kuhnke, Mirjam Hümmert, Martin W. Ringelstein, Marius Rommer, Paulus S. Ayzenberg, Ilya Ruprecht, Klemens Klotz, Luisa Asgari, Nasrin Zrzavy, Tobias Höftberger, Romana Tobia, Rafik Buttmann, Mathias Fechner, Kai Schanda, Kathrin Weber, Martin Asseyer, Susanna Haas, Jürgen Lechner, Christian Kleiter, Ingo Aktas, Orhan Trebst, Corinna Rostasy, Kevin Reindl, Markus Kümpfel, Tania Paul, Friedemann Wildemann, Brigitte |
author_facet | Jarius, Sven Pellkofer, Hannah Siebert, Nadja Korporal-Kuhnke, Mirjam Hümmert, Martin W. Ringelstein, Marius Rommer, Paulus S. Ayzenberg, Ilya Ruprecht, Klemens Klotz, Luisa Asgari, Nasrin Zrzavy, Tobias Höftberger, Romana Tobia, Rafik Buttmann, Mathias Fechner, Kai Schanda, Kathrin Weber, Martin Asseyer, Susanna Haas, Jürgen Lechner, Christian Kleiter, Ingo Aktas, Orhan Trebst, Corinna Rostasy, Kevin Reindl, Markus Kümpfel, Tania Paul, Friedemann Wildemann, Brigitte |
author_sort | Jarius, Sven |
collection | PubMed |
description | BACKGROUND: New-generation cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD). OBJECTIVE: To describe systematically the CSF profile in MOG-EM. MATERIAL AND METHODS: Cytological and biochemical findings (including white cell counts and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgA/IgM fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster (MRZ) reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF l-lactate) from 163 lumbar punctures in 100 adult patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively. RESULTS: Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in almost 90% of samples (N = 151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 62). If present, intrathecal IgG (and, more rarely, IgM) synthesis was low, often transient and mostly restricted to acute attacks. CSF WCC was elevated in > 50% of samples (median 31 cells/μl; mostly lymphocytes and monocytes; > 100/μl in 12%). Neutrophils were present in > 40% of samples; activated lymphocytes were found less frequently and eosinophils and/or plasma cells only very rarely (< 4%). Blood–CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 48% of all samples and at least once in 55% of all patients (N = 88) tested. The frequency and degree of CSF alterations were significantly higher in patients with acute myelitis than in patients with acute ON and varied strongly depending on attack severity. CSF l-lactate levels correlated significantly with the spinal cord lesion load in patients with acute myelitis (p < 0.0001). Like pleocytosis, blood–CSF barrier dysfunction was present also during remission in a substantial number of patients. CONCLUSION: MOG-IgG-positive EM is characterized by CSF features that are distinct from those in MS. Our findings are important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease. |
format | Online Article Text |
id | pubmed-7470615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74706152020-09-08 Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients Jarius, Sven Pellkofer, Hannah Siebert, Nadja Korporal-Kuhnke, Mirjam Hümmert, Martin W. Ringelstein, Marius Rommer, Paulus S. Ayzenberg, Ilya Ruprecht, Klemens Klotz, Luisa Asgari, Nasrin Zrzavy, Tobias Höftberger, Romana Tobia, Rafik Buttmann, Mathias Fechner, Kai Schanda, Kathrin Weber, Martin Asseyer, Susanna Haas, Jürgen Lechner, Christian Kleiter, Ingo Aktas, Orhan Trebst, Corinna Rostasy, Kevin Reindl, Markus Kümpfel, Tania Paul, Friedemann Wildemann, Brigitte J Neuroinflammation Research BACKGROUND: New-generation cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD). OBJECTIVE: To describe systematically the CSF profile in MOG-EM. MATERIAL AND METHODS: Cytological and biochemical findings (including white cell counts and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgA/IgM fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster (MRZ) reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF l-lactate) from 163 lumbar punctures in 100 adult patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively. RESULTS: Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in almost 90% of samples (N = 151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 62). If present, intrathecal IgG (and, more rarely, IgM) synthesis was low, often transient and mostly restricted to acute attacks. CSF WCC was elevated in > 50% of samples (median 31 cells/μl; mostly lymphocytes and monocytes; > 100/μl in 12%). Neutrophils were present in > 40% of samples; activated lymphocytes were found less frequently and eosinophils and/or plasma cells only very rarely (< 4%). Blood–CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 48% of all samples and at least once in 55% of all patients (N = 88) tested. The frequency and degree of CSF alterations were significantly higher in patients with acute myelitis than in patients with acute ON and varied strongly depending on attack severity. CSF l-lactate levels correlated significantly with the spinal cord lesion load in patients with acute myelitis (p < 0.0001). Like pleocytosis, blood–CSF barrier dysfunction was present also during remission in a substantial number of patients. CONCLUSION: MOG-IgG-positive EM is characterized by CSF features that are distinct from those in MS. Our findings are important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease. BioMed Central 2020-09-03 /pmc/articles/PMC7470615/ /pubmed/32883348 http://dx.doi.org/10.1186/s12974-020-01824-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Jarius, Sven Pellkofer, Hannah Siebert, Nadja Korporal-Kuhnke, Mirjam Hümmert, Martin W. Ringelstein, Marius Rommer, Paulus S. Ayzenberg, Ilya Ruprecht, Klemens Klotz, Luisa Asgari, Nasrin Zrzavy, Tobias Höftberger, Romana Tobia, Rafik Buttmann, Mathias Fechner, Kai Schanda, Kathrin Weber, Martin Asseyer, Susanna Haas, Jürgen Lechner, Christian Kleiter, Ingo Aktas, Orhan Trebst, Corinna Rostasy, Kevin Reindl, Markus Kümpfel, Tania Paul, Friedemann Wildemann, Brigitte Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients |
title | Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients |
title_full | Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients |
title_fullStr | Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients |
title_full_unstemmed | Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients |
title_short | Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients |
title_sort | cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (mog) antibodies. part 1: results from 163 lumbar punctures in 100 adult patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470615/ https://www.ncbi.nlm.nih.gov/pubmed/32883348 http://dx.doi.org/10.1186/s12974-020-01824-2 |
work_keys_str_mv | AT jariussven cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT pellkoferhannah cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT siebertnadja cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT korporalkuhnkemirjam cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT hummertmartinw cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT ringelsteinmarius cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT rommerpauluss cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT ayzenbergilya cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT ruprechtklemens cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT klotzluisa cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT asgarinasrin cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT zrzavytobias cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT hoftbergerromana cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT tobiarafik cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT buttmannmathias cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT fechnerkai cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT schandakathrin cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT webermartin cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT asseyersusanna cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT haasjurgen cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT lechnerchristian cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT kleiteringo cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT aktasorhan cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT trebstcorinna cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT rostasykevin cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT reindlmarkus cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT kumpfeltania cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT paulfriedemann cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT wildemannbrigitte cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients AT cerebrospinalfluidfindingsinpatientswithmyelinoligodendrocyteglycoproteinmogantibodiespart1resultsfrom163lumbarpuncturesin100adultpatients |